Selected articles
Articles for label Pešťál Adam are displayed.. Show all articles
Surgery treatment of lung cancer
05/2019 MUDr. Adam Peštál, Ph.D.
Surgery is mostly used to treat non-small cell lung cancer in early stage I and II. Surgery can be used in stage IIIA but also together with chemoradiotherapy. Surgery is not normally used to treat small cell cancer; small cell lung cancer is treated only with T1—2(3) NO M0 attributes. The aim of surgery treatment is complete removal of tumorous cells (RO) with surrounding lymphatic tissue.
ENTIRE ARTICLE
Surgery is mostly used to treat non-small cell lung cancer in early stage I and II. Surgery can be used in stage IIIA but also together with chemoradiotherapy. Surgery is not normally used to treat small cell cancer; small cell lung cancer is treated only with T1—2(3) NO M0 attributes. The aim of surgery treatment is complete removal of tumorous cells (RO) with surrounding lymphatic tissue.
The targeted therapy of the patient with pulmonary metastases of colorectal cancer in a the sequence of bevacizumab‑panitumumab‑regorafenib
01/2019 MUDr. Sabina Svobodová; MUDr. Adam Peštál, Ph.D.; MUDr. Igor Suškevič
In the course of the disease more than half of the patients with colorectal cancer creates metastases to distant organs. The liver is the first site of metastases in 80 %, followed by the lungs. The basis of the system of treatment of metastatic colorectal cancer is chemotherapy. This targeted therapy increases its beneficence. An important therapeutic modality is surgical resection of metastases, which has the potential to improve overall survival, which today exceeds 30 months. The case report demonstrates that suitably elected treatment can achieve a multimodal overall survival of the patient and a good quality of life even in the metastatic stage of oncological disease approximately in years. It shows the current options for the targeted treatment of metastatic colorectal cancer. It confirms the long-term efficacy of the targeted treatment, maintaining good effect while applying a sequence of VEGF antibodies against anti EGFR inhibitor.
ENTIRE ARTICLE
In the course of the disease more than half of the patients with colorectal cancer creates metastases to distant organs. The liver is the first site of metastases in 80 %, followed by the lungs. The basis of the system of treatment of metastatic colorectal cancer is chemotherapy. This targeted therapy increases its beneficence. An important therapeutic modality is surgical resection of metastases, which has the potential to improve overall survival, which today exceeds 30 months. The case report demonstrates that suitably elected treatment can achieve a multimodal overall survival of the patient and a good quality of life even in the metastatic stage of oncological disease approximately in years. It shows the current options for the targeted treatment of metastatic colorectal cancer. It confirms the long-term efficacy of the targeted treatment, maintaining good effect while applying a sequence of VEGF antibodies against anti EGFR inhibitor.